ACM
ADAR1 Capital Management Portfolio holdings
AUM
$1.34B
1-Year Est. Return
288.83%
This Fund
S&P 500
1 Year Est. Return
+288.83%
AUM
$1.34B
AUM Growth
+$327M
(+32%)
Holding
284
Top Buys
| 1 | +$31.8M | |
| 2 | +$14.2M | |
| 3 | +$12.6M | |
| 4 |
Terns Pharmaceuticals
TERN
|
+$12.3M |
| 5 |
Arbutus Biopharma
ABUS
|
+$11.3M |
Top Sells
| 1 | +$94.2M | |
| 2 | +$31.1M | |
| 3 | +$15.5M | |
| 4 |
MTSR
Metsera Inc
MTSR
|
+$7.98M |
| 5 |
Invivyd
IVVD
|
+$7.22M |
Sector Composition
| 1 | Healthcare | 90.32% |
| 2 | Financials | 1.75% |
| 3 | Real Estate | 0.13% |
| 4 | Communication Services | 0.08% |
| 5 | Consumer Discretionary | 0.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ABVX
1
Abivax
ABVX
$8.94B
| $178M | 13.29% |
1,317,329
-33,497
|
|
||
2
Protagonist Therapeutics
PTGX
$5.89B
| $91.6M | 6.85% |
1,049,168
+59,986
|
|
||
3
Roivant Sciences
ROIV
$20.1B
| $74.4M | 5.57% |
3,428,962
+81,461
|
|
||
4
Immunovant
IMVT
$5.65B
| $63.1M | 4.72% |
2,480,968
+239,215
|
|
||
|
RNAM
5
Avidity Biosciences
RNAM
$11.2B
| $39.4M | 2.95% |
546,534
+492,878
|
|
||
6
Alpha Architect 1-3 Month Box ETF
BOXX
$10.1B
| $38.8M | 2.9% |
337,125
|
|
||
7
State Street SPDR S&P 500 ETF Trust
SPY
$695B
| $37.3M | 2.79% |
54,684
|
|
||
8
Cytokinetics
CYTK
$7.51B
| $34.3M | 2.57% |
540,166
+21,245
|
|
||
|
SEPN
9
Septerna Inc
SEPN
$1.28B
| $32.3M | 2.41% |
1,157,611
-18,880
|
|
||
|
10
Arbutus Biopharma
ABUS
$898M
| $26M | 1.95% |
5,415,109
+2,511,883
|
|
||
11
Zai Lab
ZLAB
$2.06B
| $22M | 1.64% |
1,246,520
+377,740
|
|
||
|
12
Terns Pharmaceuticals
TERN
$4.57B
| $21.9M | 1.64% |
541,615
+531,615
|
|
||
13
CytomX Therapeutics
CTMX
$905M
| $17.8M | 1.33% |
4,182,769
+137,355
|
|
||
14
Celldex Therapeutics
CLDX
$1.99B
| $17.6M | 1.31% |
646,767
+537,325
|
|
||
15
RAPT Therapeutics
RAPT
$1.68B
| $17.3M | 1.29% |
509,679
+1,908
|
|
||
16
Inhibikase Therapeutics
IKT
$234M
| $16.5M | 1.24% |
8,063,949
+2,816,346
|
|
||
17
BridgeBio Pharma
BBIO
$12.7B
| $16.3M | 1.22% |
213,414
-60,000
|
|
||
18
Monopar Therapeutics
MNPR
$357M
| $15.3M | 1.14% |
233,908
+103,909
|
|
||
19
Vaxcyte
PCVX
$8.9B
| $14.6M | 1.09% |
315,642
+102,578
|
|
||
20
Crinetics Pharmaceuticals
CRNX
$4.17B
| $14.4M | 1.08% |
309,368
+61,000
|
|
||
21
Fulcrum Therapeutics
FULC
$520M
| $14.2M | 1.06% |
1,253,749
+912,137
|
|
||
22
Prothena Corp
PRTA
$506M
| $13.9M | 1.04% |
1,457,764
-11,334
|
|
||
23
Lexeo Therapeutics
LXEO
$520M
| $13.8M | 1.03% |
1,393,161
-138,792
|
|
||
24
Taysha Gene Therapies
TSHA
$1.24B
| $13.7M | 1.03% |
2,495,809
-339,871
|
|
||
|
CDTX
25
DELISTED
Cidara Therapeutics
CDTX
| $13.2M | 0.99% |
59,677
+38,155
|
|